Neumora Therapeutics, Inc. (NMRA) Stock Forecast & Price Target
Neumora Therapeutics, Inc. · NASDAQ
$1.65+0.16 (+10.74%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Neumora Therapeutics, Inc, 7 rate it Buy or better, 1 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $3.00 to $14.00 (about 4.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.57 sits 298% above the current $1.65. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.21 next quarter toward $-0.74 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy778%
Hold111%
Sell111%
Strong Sell00%
Based on 9 analysts giving stock ratings to Neumora Therapeutics, Inc.
As of Jul, 7 of 9 firms rate NMRA a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
NMRA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.21
Range $-0.32 – $-0.17 · 9 analysts · -41% YoY
Next period, 9 analysts expect Neumora Therapeutics, Inc. to earn $-0.21 a share (range $-0.32 – $-0.17), versus $-0.35 a year earlier. Full-year consensus is $-0.92, growing to $-0.74 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $1.3M next year.
Top analysts covering Neumora Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NMRA.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$14.00+748.5% to target
Overall win rate
52%
+ Follow
#2
Ami Fadia
Needham · Rank #90
Buy
$5.00+203.0% to target
Overall win rate
46%
+ Follow
#3
Douglas Tsao
HC Wainwright & Co. · Rank #212
Buy
$7.00+324.2% to target
Overall win rate
35%
+ Follow
#4
Brian Abrahams
RBC Capital · Rank #311
Buy
$5.00+203.0% to target
Overall win rate
25%
+ Follow
#5
TR
Tessa Romero
JP Morgan
Sell
No targeton NMRA
Coverage
—
+ Follow
NMRA stock forecast FAQ
What is NMRA's average 12-month price target?+
The 7 analysts with a live target average $6.57 for Neumora Therapeutics, Inc. over the next 12 months, ranging from a $14.00 high to a $3.00 low.
Is NMRA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 7 are Buy or Strong Buy, 1 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for NMRA?+
The Street-high target is $14.00 (Guggenheim), and the Street-low is $3.00 (Stifel). The average of all 7 active targets is $6.57.
How many Wall Street analysts cover NMRA?+
9 analysts have an active rating on Neumora Therapeutics, Inc., and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering NMRA?+
Among analysts who currently cover NMRA, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $14.00 target.
What is Neumora Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.21 per share (range $-0.32 – $-0.17) across 9 analysts. Full-year EPS is projected at $-0.92, rising to $-0.74 the following year.
How much revenue is Neumora Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $1.3M next year.
Have analysts been upgrading or downgrading NMRA lately?+
As of Jul, 7 of 9 firms rate NMRA a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NMRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
